A novel irreversible antagonist of the A1-adenosine receptor

M Srinivas, JC Shryock, PJ Scammells, J Ruble, SP Baker and L Belardinelli

Department of Pharmacology, University of Florida, Gainesville, USA.

We determined the effects of 8-cyclopentyl-3-[3-[[4- (fluorosulfonyl)benzoyl]oxy]propyl]-1-propylxanth ine (FSCPX), a putative irreversible antagonist of the A1-adenosine receptor, on cardiac A1-adenosine receptor-mediated responses and on the specific binding of [3H]-8-cyclopentyl-1,3-dipropylxanthine ([3H]CPX) to guinea pig cardiac and brain membranes. FSCPX (5 microM) completely reversed the increase in K+ current of guinea pig atrial myocytes caused by 100 microM adenosine (259 +/- 30 to 20 +/- 7 pA) but had no significant effect on K+ currents caused by either 0.5 microM carbachol or 100 microM GTP gamma S. The attenuation of K+ current by FSCPX was both time and concentration dependent and persisted after washout of the antagonist. Pretreatment of atrial myocytes with FSCPX (50 nM) markedly attenuated the activation of K+ current and the inhibition of isoproterenol-stimulated I(Ca,L) caused by adenosine by 90.1% and 84.2%, respectively, but did not alter the responses of atrial myocytes to carbachol. FSCPX (1 microM) irreversibly antagonized the A1- adenosine receptor-mediated increase in atrioventricular nodal conduction time of isolated perfused guinea pig hearts from 10.5 +/- 0.5 to 0.7 +/- 0.6 msec but did not significantly alter the A2- adenosine receptor-mediated decrease in coronary resistance. Preincubation of guinea pig cardiac membranes with 0.1, 1.0, or 3.0 microM FSCPX for 30 min reduced the Bmax of [3H]CPX binding by 41 +/- 10%, 67 +/- 6%, and 80 +/- 1% (mean +/- standard error, three experiments), respectively, with no significant change in the Kd. Similarly, 0.1 and 1.0 microM FSCPX irreversibly reduced the binding of [3H]CPX to guinea pig forebrain membranes by 65 +/- 5% and 83 +/- 2% (four experiments), respectively, but did not reduce the binding of [3H]CGS 21680, an A2a-adenosine receptor agonist, to striatal membranes. FSCPX did not affect the potency of 5'- guanylylimidodiphosphate to inhibit the binding of [3H]CCPA, an A1- adenosine receptor agonist, to brain membranes. The results indicate that FSCPX is a specific, irreversible, A1-adenosine subtype-selective receptor antagonist.

Volume 50, Issue 1, pp. 196-205, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. Kulick, C. Panico, P. Gill, and W. J. Welch Low salt intake increases adenosine type 1 receptor expression and function in the rat proximal tubule Am J Physiol Renal Physiol, July 1, 2008; 295(1): F37 - F41. [Abstract] [Full Text] [PDF]

				J. E. Wunderlich, B. J. Needleman, Z. Chen, J. G. Yu, Y. Wang, I. Grants, D. J. Mikami, W. S. Melvin, H. J. Cooke, and F. L. Christofi Dual purinergic synaptic transmission in the human enteric nervous system Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G554 - G566. [Abstract] [Full Text] [PDF]

				M. Srinivas, J. C. Shryock, D. M. Dennis, S. P. Baker, and L. Belardinelli Differential A1 Adenosine Receptor Reserve for Two Actions of Adenosine on Guinea Pig Atrial Myocytes Mol. Pharmacol., October 1, 1997; 52(4): 683 - 691. [Abstract] [Full Text]